Former U.S. Department of Commerce Trade Representative to Assist HTDS

SHENZHEN, China, Dec. 8 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com Hard to Treat Diseases, Inc. (HTDS) announced the release of its Q3 results today. The company reported gross revenues of $ 481,949.00 for the quarter and the profit was at a break even. The company expects to finish the year in the black or a profit level. The delay of issuance of the Q3 did serve its purpose (as HTDS stock could not be borrowed) and more importantly some of the brokers who previously only allowed "sell only" orders are finally allowing both buy and sell orders on HTDS security. Notwithstanding, the company is advised that the "skull and bones" rank posted on Pink Sheets will remain as a rank on HTDS security, regardless of the fact that HTDS is current in its filings, has completed the adequate disclosure and is fully transparent. Further to the news of December 7 2009 the company is in a litigation mode and in discussions with US based barristers to seek relief through legal remedies.

Carol Robichaud, Secretary of HTDS said "Be that as it may HTDS is a viable strong resilient company. We are focusing our efforts on new business, new contracts, new revenue streams such as different International expansions and as highlighted in our December 7 2009 release, various options available through our Slavica Bio Chem division. To that end we are pleased to announce the appointment of Mr. Rudolph M. Dahl as a marketing advisor to HTDS.

Mr. Dahl has over 30 years experience in governmental relations, contracting and policy representation. At one time Mr. Dahl was a leading international trade representative for the U.S. Department of Commerce. Mr. Dahl is currently President of Global Holdings, an international infrastructure firm. He is a former U.S. Navy officer and has a B.S. in Physics and Mathematics from the University of Minnesota.

At the present Mr. Dahl is currently working with countries in Africa, Asia, and the Caribbean to provide logistics, communications, and medicines to plan for and handle disasters such as pandemic H1N1 and Avian Flu outbreaks. He will specify appropriate medications for such disasters and their distribution sequencing.

"We are enthusiastic about having Mr. Dahl on our team in light of his extensive international contacts and marketing experience," said Terry Yuan, CEO of HTDS. "We believe that he will be instrumental in our rapid roll-out of our H1N1 vaccine and other products in Africa, South America and Asia."

HTDS has two subsidiaries, Slavica Bio Chem Co and China Mellow Hope Inc. www.mellowhope.com. Slaivca's primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatis C. Mellow Hope is China-based and is the biggest exporter of Biological Vaccines in China. It has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestatin.

To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today at www.minamargroup.com/updates

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk

SOURCE Hard to Treat Diseases